Published in N Engl J Med on October 07, 1999
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol (2009) 3.74
Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 2.74
Eosinophilia--idiopathic or not? N Engl J Med (1999) 2.41
Marked and persistent eosinophilia in the absence of clinical manifestations. J Allergy Clin Immunol (2013) 2.12
Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol (2008) 2.04
Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Natl Acad Sci U S A (2005) 1.92
Hypereosinophilic syndromes. Orphanet J Rare Dis (2007) 1.53
Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am (2007) 1.37
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood (2014) 1.32
Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 1.25
Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol (2010) 1.25
T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica (2009) 1.20
BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J Mol Diagn (2005) 1.17
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol (2012) 1.15
Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice. J Invest Dermatol (2010) 1.14
Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. Haematologica (2009) 1.09
How I treat hypereosinophilic syndromes. Blood (2009) 1.07
Adult eosinophilic gastroenteritis and hypereosinophilic syndromes. World J Gastroenterol (2008) 0.99
Gastrointestinal eosinophilia. Immunol Allergy Clin North Am (2007) 0.98
The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood (2006) 0.97
NIK prevents the development of hypereosinophilic syndrome-like disease in mice independent of IKKα activation. J Immunol (2012) 0.96
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol (2012) 0.94
Therapeutic approaches to patients with hypereosinophilic syndromes. Semin Hematol (2012) 0.92
How I treat hypereosinophilic syndromes. Blood (2015) 0.91
A patient with hypereosinophilic syndrome that manifested with acquired hemophilia and elevated IgG4: a case report. J Med Case Rep (2012) 0.88
ICON: Eosinophil Disorders. World Allergy Organ J (2012) 0.88
FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem (2009) 0.86
Advances in diagnosis and treatment of eosinophilia. Curr Opin Hematol (2009) 0.86
The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Medicine (Baltimore) (2014) 0.85
Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection. Pediatr Blood Cancer (2009) 0.85
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol (2016) 0.84
Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia. Transl Oncogenomics (2006) 0.79
Novel Therapies for Eosinophilic Disorders. Immunol Allergy Clin North Am (2015) 0.78
Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol (2014) 0.78
A case report of nonepisodic angioedema with eosinophilia in a Korean patient and a review of the Korean literature. Korean J Intern Med (2006) 0.78
Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome. Blood (2013) 0.77
A rare manifestation of idiopathic hypereosinophilic syndrome: sclerosing cholangitis. Dig Dis Sci (2002) 0.77
Hypereosinophilia in Children and Adults: A Retrospective Comparison. J Allergy Clin Immunol Pract (2016) 0.75
Idiopathic eosinophilia. N Engl J Med (2000) 0.75
Idiopathic hypereosinophilic syndrome: a rare cause of erythroderma. J Dermatol Case Rep (2014) 0.75
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. J Invest Dermatol (2016) 0.75
CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica (2015) 0.75
Idiopathic eosinophilia. N Engl J Med (2000) 0.75
GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma. Oncotarget (2016) 0.75
Idiopathic eosinophilic pneumonia in children: the French experience. Orphanet J Rare Dis (2014) 0.75
Idiopathic eosinophilia. N Engl J Med (2000) 0.75
Eosinophilia: introduction. Semin Hematol (2012) 0.75
Eosinophilia in Hematologic Disorders. Immunol Allergy Clin North Am (2015) 0.75
Dysregulation of interleukin 5 expression in familial eosinophilia. Allergy (2017) 0.75
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med (1999) 3.37
Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am J Respir Crit Care Med (1994) 3.13
An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods (1991) 2.96
Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis (1992) 2.89
Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol (2001) 2.62
Role of interleukin 10 in specific immunotherapy. J Clin Invest (1998) 2.57
Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature (2001) 2.01
T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol (1991) 1.98
Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol (1991) 1.92
SAPALDIA: methods and participation in the cross-sectional part of the Swiss Study on Air Pollution and Lung Diseases in Adults. Soz Praventivmed (1997) 1.88
T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest (2000) 1.85
Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood (2001) 1.74
Mechanisms of interleukin-10-mediated immune suppression. Immunology (2001) 1.70
Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy (1997) 1.69
Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol (1991) 1.68
Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia? Immunol Today (1995) 1.66
A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med (1991) 1.59
Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mechanism to accumulate effector cells in inflammation. Proc Natl Acad Sci U S A (1999) 1.56
Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol (1998) 1.52
Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer (1997) 1.50
Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J Exp Med (1995) 1.47
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Basal cell carcinomas in a tertiary referral centre: a systematic analysis. Br J Dermatol (2014) 1.46
PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res (2001) 1.42
In melanoma, beta-catenin is a suppressor of invasion. Oncogene (2011) 1.40
The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther (1998) 1.36
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol (2001) 1.35
Bee venom phospholipase A2-specific T cell clones from human allergic and non-allergic individuals: cytokine patterns change in response to the antigen concentration. Eur J Immunol (1992) 1.33
Sputum eosinophils from asthmatics express ICAM-1 and HLA-DR. Clin Exp Immunol (1991) 1.30
IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol (2000) 1.30
Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest (1996) 1.29
Skin-homing, CLA+ memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: IgG4 counter-regulation by CLA- memory T cells. J Immunol (1997) 1.27
Display of expression products of cDNA libraries on phage surfaces. A versatile screening system for selective isolation of genes by specific gene-product/ligand interaction. Eur J Biochem (1994) 1.25
Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med (1996) 1.24
Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
Cloning and expression of recombinant Aspergillus fumigatus allergen I/a (rAsp f I/a) with IgE binding and type I skin test activity. J Immunol (1992) 1.19
Protein-tyrosine phosphorylation regulates apoptosis in human eosinophils and neutrophils. Proc Natl Acad Sci U S A (1994) 1.19
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol (1997) 1.17
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol (2011) 1.16
A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J (2000) 1.16
Humoral and cell-mediated autoimmunity in allergy to Aspergillus fumigatus. J Exp Med (1996) 1.14
IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J (1999) 1.13
Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA. Clin Exp Allergy (2000) 1.12
Skin homing (cutaneous lymphocyte-associated antigen-positive) CD8+ T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. J Immunol (1999) 1.11
Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore. Eur J Immunol (1993) 1.11
Cutaneous lymphomas consist of a spectrum of nosologically different entities including mycosis fungoides and small plaque parapsoriasis. Arch Dermatol (1996) 1.09
Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br J Dermatol (2003) 1.09
Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med (1996) 1.08
Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J (2001) 1.08
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood (1998) 1.07
A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood (1996) 1.07
A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol (2008) 1.06
The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol (2007) 1.06
Purified recombinant A. fumigatus allergens induce different responses in mice. Clin Immunol (2001) 1.06
Humoral and cell-mediated autoimmune reactions to human acidic ribosomal P2 protein in individuals sensitized to Aspergillus fumigatus P2 protein. J Exp Med (1999) 1.06
Induction and function of eosinophil intercellular adhesion molecule-1 and HLA-DR. J Immunol (1992) 1.05
Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis. Int Immunol (1998) 1.03
Lambda2 light chains in normal mouse immunoglobulins. Proc Natl Acad Sci U S A (1978) 1.03
Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood (1998) 1.02
IL-8 is expressed by human peripheral blood eosinophils. Evidence for increased secretion in asthma. J Immunol (1995) 1.02
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer (2001) 1.02
Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. J Invest Dermatol (2001) 1.00
T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol (1993) 1.00
Cloning Aspergillus fumigatus allergens by the pJuFo filamentous phage display system. Int Arch Allergy Immunol (1996) 1.00
Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol (2000) 0.99
Immune regulation in atopic dermatitis. Curr Opin Immunol (2000) 0.99
Allergens of Aspergillus fumigatus and Candida boidinii share IgE-binding epitopes. Am J Respir Crit Care Med (1997) 0.99
Suppression of the benzylpenicilloyl- (BPO) specific IgE formation with isologous anti-idiotypic antibodies in BALB/c mice. J Immunol (1980) 0.98
T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol (2000) 0.98
MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol (1997) 0.98
Expression and function of the Fas receptor on human blood and tissue eosinophils. Eur J Immunol (1996) 0.98
Interleukin-4 induces tissue eosinophilia in mice: correlation with its in vitro capacity to stimulate the endothelial cell-dependent selective transmigration of human eosinophils. J Lab Clin Med (1993) 0.97
Allergy and immunity to fungal infections and colonization. Eur Respir J (2002) 0.97
Platelet-activating factor exerts mitogenic activity and stimulates expression of interleukin 6 and interleukin 8 in human lung fibroblasts via binding to its functional receptor. J Exp Med (1996) 0.96
Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie (2004) 0.96
Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol (2000) 0.96
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer (2010) 0.96
Induction and differential regulation of bee venom phospholipase A2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells. J Allergy Clin Immunol (1997) 0.95
Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur J Immunol (1997) 0.95
Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med (Berl) (2001) 0.95
Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol (1998) 0.95
Primary cutaneous lymphoma: two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre. Br J Dermatol (2011) 0.94
Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res (1998) 0.94
Epidermal H(2)O(2) accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: identification of a general mechanism in regulation of all 6BH4-dependent processes? J Invest Dermatol (2001) 0.94
Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res (1996) 0.94
The differential fate of cadherins during T-cell-induced keratinocyte apoptosis leads to spongiosis in eczematous dermatitis. J Invest Dermatol (2001) 0.94
SARA and Hgs attenuate susceptibility to TGF-beta1-mediated T cell suppression. FASEB J (2003) 0.94
Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals. Int Arch Allergy Immunol (1994) 0.94
Method for simultaneous RNA and DNA isolation from biopsy material, culture cells, plants and bacteria. Biotechniques (1997) 0.94
Expression of cutaneous lymphocyte-associated antigen on human CD4(+) and CD8(+) Th2 cells. Eur J Immunol (2000) 0.93
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol (2006) 0.93